Zura Bio posts corporate overview highlighting tibulizumab dual IL-17/BAFF bispecific program in Phase 2 development
ZURA•Corporate overview highlights tibulizumab program
- Zura Bio highlighted tibulizumab, a bispecific antibody designed to inhibit IL-17 and BAFF across multiple immune-mediated diseases.
- Phase 2 hidradenitis suppurativa topline data targeted for Q4 2026; systemic sclerosis topline data expected in 1H 2027.
- Polymyalgia rheumatica Phase 2 study planned to start by year-end 2026.
- Phase 1/1b program dosed 78 participants; median trough target engagement exceeded 98% for IL-17 and BAFF at 300 mg Q4W.
- Cash runway projected through at least year-end 2028.
